News Briefing channel feed

Achillion's CEO Milind Desh­pande steps down; Neu­ro­Vi­sion rais­es $11.2M for nov­el Alzheimer's de­tec­tion tech

8 years ago

Pfiz­er cuts five can­cer pro­grams; George Church en­gages Cel­lec­tis' TAL­EN tech to cre­ate virus-re­sis­tant hu­man cells

8 years ago

Two biotechs hunt $175 mil­lion in Nas­daq pur­suit; Keryx CEO Gre­go­ry Madi­son abrupt­ly re­signs; Rx­Cel­er­ate buys bio­an­a­lyt­i­cal CRO

8 years ago

Achao­gen earns $12M award for next-gen an­tibi­otics; En­do ac­quires Som­er­set for $190M

8 years ago

Ab­b­Vie ad­vances its two star pipeline ther­a­pies, fil­ing BLA for risankizum­ab and post­ing promis­ing da­ta for upadac­i­tinib

8 years ago

Sofinno­va leads $32.4 mil­lion round for Italy's Ery­Del; Cel­gene ex­pands col­lab­o­ra­tion with Zymeworks

8 years ago

Sanofi los­es its Ger­man CSO and di­a­betes chief to Grü­nen­thal; Roche touts longterm ad­van­tages of Ocre­vus in treat­ing mul­ti­ple scle­ro­sis

8 years ago

Toca­gen li­cens­es im­munother­a­py to Apol­lo­Bio for $16M up­front; WuXi AppTec un­veils ex­pand­ed lab test­ing site in New Jer­sey

8 years ago

Sanofi CFO Jerome Con­t­a­mine hits the ex­it; Strug­gling Fi­bro­cell trig­gers a strate­gic re­view

8 years ago

No­var­tis pledges $100M to malar­ia ef­forts; Lil­ly, Boehringer out­lines new Jar­diance kid­ney tri­al at Ox­ford

8 years ago

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

8 years ago

Ad­ynxx drug failed in PhII but it’s go­ing in­to PhI­II any­way; Deer­field leads $50M raise for Sol­lis

8 years ago

Pfiz­er launch­es a gene ther­a­py study for Duchenne MD; Am­gen, NEA back re­al-world drug da­ta soft­ware com­pa­ny

8 years ago

CymaBay shares soar on tri­al up­date; Lon­za opens mas­sive Texas fa­cil­i­ty ded­i­cat­ed to cell, gene ther­a­pies; In­ovio lines up $56M

8 years ago

Fra­zier adds $780M fund for its ‘growth buy­out’ team; FDA push­es back its dead­line on Ab­b­Vie's elagolix; Promethera buys NASH drug

8 years ago

Aca­dia shares plunge af­ter CNN probes Nu­plazid deaths; Agios shares surge on re­port that a shaky Cel­gene is scout­ing an­oth­er buy­out

8 years ago

No­vo Nordisk picks up sick­le-cell dis­ease drug in $400M li­cens­ing pact; Sapi­ence teams up with UK re­searcher on can­cer drugs

8 years ago

CAR-T play­er Po­sei­da march­es on with $30.5M Se­ries B; Kymera inks dis­cov­ery deal with GSK

8 years ago

As­traZeneca wins pri­or­i­ty re­view sched­ule for leukemia drug; Penn gene ther­a­py up­start grabs $9.29M with Fra­zier's help

8 years ago

As­traZeneca hands Com­pu­gen $10M to launch I/O dis­cov­ery deal; RA Cap­i­tal joins op­po­si­tion to pro­posed BioCryst/Idera merg­er

8 years ago

Glob­al CRO WuXi AppTec looks to raise $900M-plus from Shang­hai IPO; Edge shares crushed on PhI­II fail­ure

8 years ago

Roivant bags Chi­na rights to Nabri­va's an­tibi­ot­ic; Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal can­cer drug stud­ies

8 years ago

With Big Phar­ma castoffs in hand, Mereo files for $81M IPO; Lon­don's Verona sees stock surge on PhI­Ib COPD da­ta

8 years ago

Helsinn buys glob­al rights for skin can­cer drug from Acte­lion; Ake­bia reels in more cash for vadadu­s­tat; EMA slams Bevyxxa

8 years ago
First page Previous page 60616263646566 Next page Last page
A service from the Financial Times